
BIO International Convention
June 14, 2025
Boston, United States
Our CEO Marc Dechamps will be attending BIO this year. He will be connecting with fellow biotech innovators and potential pharmaceutical partners at this landmark industry event.
We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice
Cookies settings I agree I disagreeCookies information
Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:
These settings will be kept for 24h
Bioxodes’ innovative pipeline includes a clinical-stage program for the prevention of thrombosis and neuroinflammation in patients with intracerebral hemorrhage (ICH). Bioxodes is also preparing a Phase 2 trial with BIOX-101 in ischemic stroke.
BIOX-101 demonstrates a powerful dual mode of action, targeting thromboinflammation at its source. It inhibits the activation of neutrophils – the human immune system’s first responders - and the release of neutrophil extracellular traps (NETs). It also inhibits Factors XIa and XIIa of the intrinsic coagulation pathway, exerting a powerful antithrombotic effect. Crucially, it does so without increasing bleeding.
In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of BIOX-101 against neutrophil activation and NETs formation.
BIOX-101 is our lead asset, topping a pipeline of therapeutic candidates targeting thrombo-inflammatory diseases. We are currently preparing for a Phase 2b clinical trial of BIOX-101 in intracerebral hemorrhage (ICH), a condition with significant unmet medical need. BIOX-101 has received Orphan Drug Designation in both Europe and the U.S. for this indication.
“Stroke is worldwide one of the main causes for mortality,” he says in this video. “We are really in need to find medication hear to try and improve their prognosis.” Professor Lemmens, the head of the stroke unit at the University Hospital Leuven (Belgium), was speaking at an investor event Bioxodes had organized in Zurich, in February 2024.
First-in-class clinical-stage therapeutic to treat intracerebral hemorrhage, an often lethal disease with no approved treatment.
Innovative pipeline targeting multiple thrombo-inflammatory indications and with ambitious discovery program.
Launching a potentially registrational Phase 2b trial for BIOX-101. Considering a Phase 2 trial for ischemic stroke.
BIO International Convention
June 14, 2025
Boston, United States
Our CEO Marc Dechamps will be attending BIO this year. He will be connecting with fellow biotech innovators and potential pharmaceutical partners at this landmark industry event.
European Stroke Organisation Conference 2025
May 21, 2025
Helsinki, Finland
Part of Bioxodes team will be attending the European Stroke Organisation Congress (ESOC) this year.
BioEquity Europe
May 12, 2025
Bruges, Belgium
Our CEO Marc Dechamps will be presenting at the 25th edition of BioEquity Europe in Bruges
Can Bioxodes end the dearth of haemorrhagic stroke drugs?
April 29, 2025
Front page article in Pharmaphorum by Phil Taylor There is currently no approved treatment for intracerebral haemorrhagic (ICH) stroke, but Belgian start-up Bioxodes hopes to change that with a drug based on a protein found in the saliva of ticks.
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
All investors